youtube_live
Q2 2027 earnings • released • EPS beat +58.88% • Revenue beat +716.75%
See resultschevron_right
ROIV:NASDAQ
Roivant Sciences Ltd
$39.53
arrow_downward
-1.15%(-0.46) 1D
$39.53
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 13, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ROIV...
Open
$39.82
High
$39.88
Low
$39.16
Mkt. cap
28.64B
Avg. vol.
7.46M
Volume
7.19M
52-wk high
$42.50
52-wk low
$19.96
EPS
-$0.49
Beta
1.23
Shares outstanding
724.56M
No. of employees
721
Open
$39.82
High
$39.88
Low
$39.16
Mkt. cap
28.64B
Avg. vol.
7.46M
Volume
7.19M
52-wk high
$42.50
52-wk low
$19.96
EPS
-$0.49
Beta
1.23
Shares outstanding
724.56M
No. of employees
721
News stories
From web sources and news partners
www.marketscreener.com
·
20 hours ago
Roivant Sciences Insider Sold Shares Worth $12,473,272, According to a Recent SEC Filing
GuruFocus
·
1 day ago
Roivant Sciences (ROIV) Insider Sale: President & Immunovant CEO Eric Venker Offloads 187,943 Shares
TradingView
·
1 day ago
Roivant Sciences CFO Sold Shares Worth Over $12M
Profile
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel. Wikipedia
About Roivant Sciences Ltd
CEOMatt Gline
Employees721
FoundedApr 7, 2014
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteroivant.com